BioChemics, Inc. Announces Expanded Scope of Collaboration with a Leading Light Based Technology Company

DANVERS, Mass.--(BUSINESS WIRE)--BioChemics, Inc. (BCI), a company “enhancing drug delivery through biophysical modulation,” is pleased to announce that it has expanded the scope of its research collaboration agreement with Cynosure, Inc. (NASDAQ:CYNO), a leading developer and manufacturer of light-based aesthetic treatment systems. The expanded scope of the agreement is to evaluate the use of BCI's VALE® based technology in conjunction with light based aesthetic treatments. BioChemics is a specialty pharmaceutical company that has developed a novel, transdermal drug delivery system called VALE® (Vaso-active Lipid Encapsulated), that allows a wide variety of actives to be delivered into the skin.